Literature DB >> 20532027

A multidimensional approach to medication selection in the treatment of children and adolescents with ADHD.

Atilla Turgay1.   

Abstract

The objective of this paper is to outline clinical patient characteristics to individualize medication selection for children and adolescents with ADHD. The treatment guidelines and clinical parameters outlined in this paper are based on clinical research and evidence- and/or consensus-based guidelines for medication treatment of children and adolescents with ADHD and associated symptoms or comorbid disorders. Recommendations are made for medication selection in different clinical situations. The increased availability of ADHD medications over the past few years has provided a number of treatment options with longer symptom control and improved the remission or "multidimensional normalization" for ADHD patients. Selection of the most appropriate medication(s) for complicated cases may present a serious challenge in some situations. This paper outlines selected complicated cases and treatment options.

Entities:  

Keywords:  ADHD; adolescents; aggressive disorders; anxiety disorders; attention deficity hyperactivity disorder; children; conduct disorder; depression; oppositional defiance disorder; pharmacology

Year:  2007        PMID: 20532027      PMCID: PMC2882286     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  21 in total

1.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

2.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

3.  Clonidine in child and adolescent psychiatry.

Authors:  R D Hunt; L Capper; P O'Connell
Journal:  J Child Adolesc Psychopharmacol       Date:  1990       Impact factor: 2.576

4.  Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

Authors:  David Michelson; Albert J Allen; Joan Busner; Charles Casat; David Dunn; Christopher Kratochvil; Jeffrey Newcorn; F Randy Sallee; R Bart Sangal; Keith Saylor; Scott West; Douglas Kelsey; Joachim Wernicke; Nancy J Trapp; Donald Harder
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

5.  Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.

Authors:  Jeffrey H Newcorn; Thomas J Spencer; Joseph Biederman; Denái R Milton; David Michelson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-03       Impact factor: 8.829

6.  Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder--United States, 2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2005-09-02       Impact factor: 17.586

7.  Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder.

Authors:  K D Gadow; J Sverd; J Sprafkin; E E Nolan; S Grossman
Journal:  Arch Gen Psychiatry       Date:  1999-04

8.  Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment.

Authors:  J M Swanson; H C Kraemer; S P Hinshaw; L E Arnold; C K Conners; H B Abikoff; W Clevenger; M Davies; G R Elliott; L L Greenhill; L Hechtman; B Hoza; P S Jensen; J S March; J H Newcorn; E B Owens; W E Pelham; E Schiller; J B Severe; S Simpson; B Vitiello; K Wells; T Wigal; M Wu
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

9.  Major Depression with ADHD: In Children and Adolescents.

Authors:  Atilla Turgay; Rubaba Ansari
Journal:  Psychiatry (Edgmont)       Date:  2006-04

10.  Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.

Authors:  Atilla Turgay; Carin Binder; Richard Snyder; Sandra Fisman
Journal:  Pediatrics       Date:  2002-09       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.